BAJAJ BROKING
Cipla, a leading pharmaceutical company, has announced its financial results for the third quarter of the fiscal year 2024-2025, ending December 31, 2024. The company reported a consolidated net profit of ₹1,574.59 crore, a significant increase from ₹1,068.51 crore in the same quarter of the previous year. This robust performance is attributed to strong demand, particularly in the North American market.
Revenue Growth: Total revenue from operations reached ₹7,072.97 crore, up from ₹6,603.81 crore in Q3 FY23.
Profit Before Tax: The company reported a profit before tax of ₹1,916.09 crore, compared to ₹1,473.81 crore in the same quarter last year.
Net Profit: Net profit after tax stood at ₹1,574.59 crore, a substantial increase from ₹1,068.41 crore in Q3 FY23.
In the third quarter, Cipla's revenue from the sale of products was ₹6,961.60 crore, up from ₹6,505.66 crore in the same period last year. Other operating revenue also saw an increase, contributing to the overall growth in total revenue from operations.
Pharmaceuticals: Strong Revenue & Profit Growth
Revenue grew 6.5% YoY to ₹6,777.84 crore, up from ₹6,365.06 crore.
Quarterly profit rose to ₹1,888.86 crore, a 10.7% YoY increase from ₹1,780.73 crore.
9M FY25 revenue stood at ₹19,942.70 crore, reflecting steady growth from ₹18,846.08 crore in 9M FY24.
New Ventures: Turnaround in Profitability
Revenue climbed to ₹341.30 crore, up 21.7% YoY from ₹280.51 crore.
Segment profit stood at ₹41.87 crore, reversing a loss of ₹6.86 crore in Q3 FY24.
9M FY25 revenue grew 12.9% YoY to ₹1,014.88 crore, up from ₹898.73 crore.
Overall Performance
Total segment revenue increased 7.1% YoY to ₹7,119.14 crore from ₹6,645.57 crore.
Total segment profit rose 13.6% YoY to ₹1,930.73 crore, driven by strong pharma growth.
Exceptional item impact of ₹194.82 crore in new ventures affected the bottom line.
Profit before tax improved 30% YoY to ₹1,916.09 crore from ₹1,473.81 crore.
Cipla's performance has surpassed market expectations, with a nearly 49% increase in consolidated net profit, reaching ₹1,574.59 crore for the October-December quarter. This figure exceeded analysts' estimates between ₹1,170 crore and ₹1,217 crore, highlighting the company's strong market position and effective strategy execution.
Umang Vohra MD and Global CEO of Cipla quoted that “I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with a highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position.
Particulars | 31-12-2024 | 31-12-2023 |
Revenue from sale of products | 6,961.60 | 6,505.66 |
Other operating revenue | 111.37 | 98.15 |
Total revenue from operations | 7,072.97 | 6,603.81 |
Other income | 221.61 | 184.63 |
Total income | 7,294.58 | 6,788.44 |
Cost of materials consumed | 1,296.73 | 1,196.18 |
Purchases of stock-in-trade | 913.23 | 927.21 |
Changes in inventories | 54.12 | 96.14 |
Employee benefits expense | 1,197.62 | 1,068.13 |
Finance costs | 14.64 | 30.10 |
Depreciation and amortisation expense | 279.80 | 233.43 |
Other expenses | 1,622.35 | 1,568.62 |
Total expenses | 5,378.49 | 5,119.81 |
Profit before tax | 1,916.09 | 1,473.81 |
Tax expense | 332.37 | 405.30 |
Net profit after tax | 1,583.72 | 1,068.51 |
Share of profit/loss of associates | (9.13) | (0.10) |
Net profit for the period | 1,574.59 | 1,068.51 |
Note: All financial figures are sourced from Cipla’s official quarterly earnings report.
The financial data for Cipla Q3 FY24-25 results is sourced from BSE.
Cipla is set to announce its Q3 FY24-25 financial results on January 28, 2025. Analysts anticipate a revenue increase of 3.1% to 7% year-over-year, with figures projected between ₹6,807 crore and ₹7,070 crore. However, margins are expected to decline both annually and sequentially.
Revenue Growth: Projected increase of 3.1% to 7% YoY, reaching ₹6,807–7,070 crore.
Profit After Tax (PAT): Estimates range from a 2.2% decrease to a 14% increase YoY, with figures between ₹1,170 crore and ₹1,217 crore.
Margin Outlook: Expected decline in margins on both YoY and sequential bases.
Key Focus Areas: Updates on drugs like Abraxane and Lanreotide, along with timelines for upcoming launches.
Analysts project Cipla's Q3 FY24-25 revenue to be in the range of ₹6,807 crore to ₹7,070 crore, reflecting a YoY growth of 3.1% to 7%. Profit after tax is estimated between ₹1,170 crore and ₹1,217 crore, indicating a potential decrease of 2.2% or an increase of up to 14% compared to the same quarter last year. Margins are anticipated to face pressure both annually and sequentially.
Note: These figures are based on analyst estimates and are subject to change upon the official release of Cipla's financial results.
The financial data estimates for Cipla Q3 FY24-25 results are sourced from Economic Times.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Bank of Baroda Q3 FY25 Results
29 Jan, 2025 | 2 Min. read
Maruti Suzuki India Q3 Results FY24-25: Revenue Increases by 15.7%
29 Jan, 2025 | 4 Min. read
Stock Market Live Updates
29 Jan, 2025 | 25 Min. read
Ambuja Cement Q3 Results FY24-25
29 Jan, 2025 | 4 Min. read
Tata Motors Q3 Results FY24-25 Highlights
29 Jan, 2025 | 4 Min. read
Bajaj Finance Q3 Results FY24-25 Highlights
29 Jan, 2025 | 3 Min. read
Bosch Q3 Results FY24-25: Revenue Increases by 6.0% YoY
28 Jan, 2025 | 3 Min. read
Exide Industries Q3 Results FY24-25 Highlights
28 Jan, 2025 | 4 Min. read
Bajaj Auto Q3 Results FY24-25 Highlights
28 Jan, 2025 | 3 Min. read
BHEL Q3 Results FY24-25, Revenue at ₹7,277 Cr
28 Jan, 2025 | 3 Min. read
Colgate-Palmolive Q3 Results FY24-25 Highlights, Revenue up by 4.7% to ₹1,452 Cr
28 Jan, 2025 | 2 Min. read
TVS Motor Company Q3 Results FY24-25 Highlights: Consolidated Revenue Up by 11%
28 Jan, 2025 | 4 Min. read
Analysis to Become a Pro Investor
28 Dec, 2023 | 4 Min. read
Women In Real Estate Investing (Investree)
28 Dec, 2023 | 5 Min. read
How To Check Prudent Corporate Advisory IPO Allotment Status
27 Dec, 2023 | 3 Min. read
How To Boost Credit Score? – Steps to Improve Creditworthiness
27 Dec, 2023 | 4 Min. read
Advantages and Disadvantages of Opening Multiple Demat Accounts
26 Dec, 2023 | 4 Min. read
7th CPC LTC: Leave Travel Concession Rules for Central Government Employees
26 Dec, 2023 | 4 Min. read
7th Pay Commission: House Building Advance (HBA) Interest Rate FY 2023-24
26 Dec, 2023 | 5 Min. read
The Future of Trading: Exploring Bajaj Broking’s Demat Features
26 Dec, 2023 | 6 Min. read
7th Central Pay Commission Cpc Fitment Table
23 Dec, 2023 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading